Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.45
CTIC's Cash to Debt is ranked higher than
67% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.62 vs. CTIC: 2.45 )
CTIC' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 2.45

Equity to Asset 0.17
CTIC's Equity to Asset is ranked higher than
52% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. CTIC: 0.17 )
CTIC' s 10-Year Equity to Asset Range
Min: -2.7   Max: 0.95
Current: 0.17

-2.7
0.95
F-Score: 5
Z-Score: -47.07
M-Score: 16.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -165.49
CTIC's Operating margin (%) is ranked higher than
66% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -57.52 vs. CTIC: -165.49 )
CTIC' s 10-Year Operating margin (%) Range
Min: -123250   Max: -119.75
Current: -165.49

-123250
-119.75
Net-margin (%) -171.53
CTIC's Net-margin (%) is ranked higher than
66% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -55.49 vs. CTIC: -171.53 )
CTIC' s 10-Year Net-margin (%) Range
Min: -169773.75   Max: -123.26
Current: -171.53

-169773.75
-123.26
ROE (%) -364.75
CTIC's ROE (%) is ranked higher than
51% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -27.70 vs. CTIC: -364.75 )
CTIC' s 10-Year ROE (%) Range
Min: -520.3   Max: -42.02
Current: -364.75

-520.3
-42.02
ROA (%) -96.87
CTIC's ROA (%) is ranked higher than
54% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -20.88 vs. CTIC: -96.87 )
CTIC' s 10-Year ROA (%) Range
Min: -261.37   Max: -20.35
Current: -96.87

-261.37
-20.35
ROC (Joel Greenblatt) (%) -1073.17
CTIC's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -212.10 vs. CTIC: -1073.17 )
CTIC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2180.72   Max: -48.38
Current: -1073.17

-2180.72
-48.38
Revenue Growth (%) 210.70
CTIC's Revenue Growth (%) is ranked higher than
100% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. CTIC: 210.70 )
CTIC' s 10-Year Revenue Growth (%) Range
Min: -100   Max: 329.2
Current: 210.7

-100
329.2
EBITDA Growth (%) -52.90
CTIC's EBITDA Growth (%) is ranked higher than
55% of the 634 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. CTIC: -52.90 )
CTIC' s 10-Year EBITDA Growth (%) Range
Min: -71.5   Max: 50.1
Current: -52.9

-71.5
50.1
EPS Growth (%) -59.50
CTIC's EPS Growth (%) is ranked higher than
55% of the 653 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. CTIC: -59.50 )
CTIC' s 10-Year EPS Growth (%) Range
Min: -74.4   Max: 64
Current: -59.5

-74.4
64
» CTIC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

CTIC Guru Trades in

Q4 2013

CTIC Guru Trades in Q4 2013

Jim Simons 285,747 sh (New)
» More
Q1 2014

CTIC Guru Trades in Q1 2014

Jim Simons Sold Out
» More
Q2 2014

CTIC Guru Trades in Q2 2014

Jim Simons 692,650 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with CTIC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about CTI Biopharma Corp

Weekly CEO Sells Highlight: Groupon Inc., Cell Therapeutics Inc., Standard Pacific Corp and Dollar General Corp
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Groupon Inc., Cell Therapeutics Inc., Standard Pacific Corp. and Dollar General Corp. Read more...

Ratios

vs
industry
vs
history
P/B 37.83
CTIC's P/B is ranked higher than
58% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.62 vs. CTIC: 37.83 )
CTIC' s 10-Year P/B Range
Min: 1.21   Max: 51.5
Current: 37.83

1.21
51.5
P/S 8.41
CTIC's P/S is ranked higher than
81% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 19.28 vs. CTIC: 8.41 )
CTIC' s 10-Year P/S Range
Min: 0.01   Max: 288
Current: 8.41

0.01
288
EV-to-EBIT -5.34
CTIC's EV-to-EBIT is ranked higher than
51% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CTIC: -5.34 )
CTIC' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -5.34

Current Ratio 1.78
CTIC's Current Ratio is ranked higher than
60% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.07 vs. CTIC: 1.78 )
CTIC' s 10-Year Current Ratio Range
Min: 0.38   Max: 24.99
Current: 1.78

0.38
24.99
Quick Ratio 1.56
CTIC's Quick Ratio is ranked higher than
62% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. CTIC: 1.56 )
CTIC' s 10-Year Quick Ratio Range
Min: 0.38   Max: 24.96
Current: 1.56

0.38
24.96

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 37.83
CTIC's Price/Tangible Book is ranked higher than
62% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 8.50 vs. CTIC: 37.83 )
CTIC' s 10-Year Price/Tangible Book Range
Min: 0.01   Max: 1492
Current: 37.83

0.01
1492
Price/Median PS Value 1.01
CTIC's Price/Median PS Value is ranked higher than
84% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 1.80 vs. CTIC: 1.01 )
CTIC' s 10-Year Price/Median PS Value Range
Min: 0.01   Max: 16799.97
Current: 1.01

0.01
16799.97
Forward Rate of Return (Yacktman) -180.66
CTIC's Forward Rate of Return (Yacktman) is ranked higher than
55% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -11.47 vs. CTIC: -180.66 )
CTIC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -180.66

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:0QUJ.UK, CTIC.Italy, CEPR.Germany
Cell Therapeutics, Inc. was incorporated in Washington in 1991. The Company is a biopharmaceutical company that develops, acquires and commercializes novel treatments for cancer. Its goal is to build a biopharmaceutical company with a diversified portfolio of proprietary oncology drugs. The Company's research, development, acquisition and in-licensing activities concentrate on identifying and developing new, less toxic and more ways to treat cancer. The Company is currently focusing on pixantrone, OPAXIO, and brostallicin. The Company is developing pixantrone, a novel anthracycline derivative, for the treatment of non-Hodgkin's lymphoma, or NHL, and various other hematologic malignancies, solid tumors and immunological disorders. Pixantrone was studied in its EXTEND, or PIX301, clinical trial, which is the first randomized, controlled, phase III single-agent clinical trial of pixantrone for patients with relapsed, aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The Company competes with pharmaceutical companies and with other specialized biotechnology companies, including Bristol-Myers Squibb Co., Sanofi-Aventis, Roche Group, Genentech, Inc., OSI Pharmaceuticals, Inc., Eli Lilly and Company, Abraxis, Neopharm Inc., Telik, Inc., TEVA Pharmaceuticals Industries Ltd. and PharmaMar. The Company is subject to federal, state and local laws, rules, regulations and policies governing the use, generation, manufacture, storage, air emission, effluent discharge, handling and disposal of certain materials, biological specimens and wastes.
» More Articles for CTIC

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Groupon Inc., Cell Therapeutics Inc., Standard Pacific Corp and Dollar G Mar 24 2014 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 
comment on CTIC Dec 16 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 50,000 Shares Feb 25 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 50,000 Shares Jan 28 2011 
Weekly CEO Sells Highlight: CTIC, DDR, UNM, BRCM, TC Jan 09 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 250,000 Shares Jan 03 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 200,000 Shares Dec 17 2010 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 150,000 Shares Dec 10 2010 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 100,000 Shares Nov 05 2010 

More From Other Websites
CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 Oct 20 2014
CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 Oct 20 2014
BrainStorm gets FDA fast-track status for ALS stem cell therapy Oct 07 2014
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Sep 30 2014
Merrimack Does Well to License Marginal Cancer Drug to Baxter Sep 24 2014
CTI BioPharma And Servier Announce Exclusive License And Collaboration Agreement To Develop And... Sep 17 2014
CTI BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD... Sep 17 2014
CTI BioPharma And Servier Announce Exclusive License And Collaboration Agreement To Develop And... Sep 17 2014
CTI BIOPHARMA CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Sep 16 2014
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Aug 28 2014
CTI BIOPHARMA CORP Financials Aug 09 2014
CTI BIOPHARMA CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Aug 07 2014
FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 Inhibitor for the... Aug 07 2014
CTI BioPharma upgraded by WallachBeth Aug 05 2014
CTI BioPharma Corp Earnings Call scheduled for 4:30 pm ET today Aug 04 2014
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Aug 04 2014
CTI BioPharma Reports Second Quarter 2014 Financial Results Aug 04 2014
Q2 2014 CTi Biopharma Corp Earnings Release - After Market Close Aug 04 2014
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jul 31 2014
The Federal Reserve Playing Analyst Damaging to Biotechnology Companies Jul 30 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK